Richtlijn: Mammacarcinoom (2.0) - Kwaliteitskoepel
Richtlijn: Mammacarcinoom (2.0) - Kwaliteitskoepel
Richtlijn: Mammacarcinoom (2.0) - Kwaliteitskoepel
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Inhoudsopgave<br />
<strong>Mammacarcinoom</strong> bij de man<br />
Gemetastaseerd mammacarcinoom..............................................................................................157<br />
Zwangerschap en fertiliteit.......................................................................................................................159<br />
Zwangerschap geassocieerd mammacarcinoom...........................................................................159<br />
Diagnostiek..............................................................................................................................159<br />
Behandeling.............................................................................................................................161<br />
Zwangerschap en borstvoeding na mammacarcinoom..................................................................166<br />
Fertiliteit na behandeling van het mammacarcinoom.....................................................................168<br />
Oorzaken onvruchtbaarheid na mammacarcinoom.................................................................168<br />
Nazorg en nacontrole................................................................................................................................170<br />
Detectie nieuwe carcinoommanifestaties.......................................................................................170<br />
Locoregionaal recidief..............................................................................................................171<br />
Detectie van een 2e primaire tumor.........................................................................................172<br />
Metastasen op afstand.............................................................................................................174<br />
Signalering en behandeling van gevolgen mammacarcinoom.......................................................174<br />
Signalering...............................................................................................................................174<br />
Locoregionale gevolgen...........................................................................................................175<br />
Gevolgen vervroegde menopauze, (neo)adjuvante hormonale therapie.................................177<br />
Psychosociale klachten en vermoeidheid................................................................................181<br />
Zorg voor de patiënt met gemetastaseerde ziekte...................................................................185<br />
Aanbevelingen nacontrole.......................................................................................................185<br />
Evaluatie van medisch handelen....................................................................................................186<br />
Organisatie van zorg.................................................................................................................................187<br />
De diagnostische fase....................................................................................................................187<br />
De behandelfase............................................................................................................................189<br />
De nazorgfase................................................................................................................................190<br />
TNM.............................................................................................................................................................193<br />
Bijlagen......................................................................................................................................................194<br />
Notities.......................................................................................................................................................206<br />
Disclaimer..................................................................................................................................................207<br />
iii